Entries by CURC

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study

/in /by

Neal D. Shore, Stephen A. Boorjian, Daniel J. Canter, Kenneth Ogan, Lawrence I. Karsh, Tracy M. Downs, Show More N.D.S., S.A.B., and D.J.C. contributed equally to the study. Purpose- Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and […]

Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer. With Dr. Neal Shore

/in /by

Recommends all Metastatic Prostate Cancer Patients Receive Genetic Testing SALT LAKE CITY, Jan. 22, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the company is applauding a new consensus statement from a team of international experts with screening recommendations on hereditary prostate cancer that […]

Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer. With Dr. Neal Shore

/in /by

Abstract Background Distinguishing between low- and high-grade prostate cancers (PCa) is important, but biopsy may underestimate the actual grade of cancer. We have previously shown that urine/plasma-based prostate-specific biomarkers can predict high grade PCa. Our objective was to determine the accuracy of a test using cell-free RNA levels of biomarkers in predicting prostatectomy results. Methods […]

The Future of Targeted Alpha Therapy. By Dr. Neal Shore

/in /by

Click here to view the video. Dr. Neal Shore discusses the evolving interest in Alpha-Emitting Radionuclide Therapy over the past 20 years, which is due to advances in the targeted delivery of radionuclides as well as increased availability of many different alpha emitters. These developments have led to a number of clinical trials in this […]

Navigating the Adverse Effects of ADT. With Dr. Neal Shore

/in /by

Click Here to watch the video. Dr. Neal Shore addresses both the perception and evidence of side effect for patients on androgen deprivation therapy (ADT). There is a growing concern about ADT side effects now that it is being used more in non-metastatic prostate cancer, which is exposing men to ADT for longer periods of […]

Updates for Optimizing GU Oncology – Interview with Neal Shore

/in /by

Charles Ryan, MD sits down with Neal Shore, MD president of the Large Urology Group Practice Association (LUGPA) who shares with listeners an overview of the 8th CME program a prelude to the annual LUGPA meeting and the agenda at this year’s LUGPA meeting. The 2017 topic for the LUGPA CME session is Updates for […]